Alkermes Q1 2026 earnings: setting the stage

Alkermes (ALKS) heads into Q1 2026 following its Q4 2025 report, where revenue was US$384.5 million and basic EPS came in at US$0.30, with net income excluding extra items of US$49.3 million. Over recent quarters, the company has reported revenue of US$429.99 million in Q4 2024, US$390.7 million in Q2 2025, and US$394.2 million in Q3 2025. Quarterly basic EPS over that period was US$0.90 in Q4 2024, US$0.50 in Q3 2025, and US$0.30 in Q4 2025. These figures leave investors focused on how current margins compare with the longer term earnings story and previously discussed growth expectations.

See our full analysis for Alkermes.

With the latest numbers in place, the next step is to weigh them against the prevailing narratives around Alkermes's growth, risks, and profitability to see which stories hold up and which ones are reconsidered.

Margins under pressure as net profit dips

• Over the last 12 months, Alkermes reported a trailing net profit margin of 16.4% on US$1.48b of revenue, compared with a 23.9% margin on US$1.56b a year earlier, so earnings grew more slowly than sales despite revenue staying in roughly the same US$1.5b range.
• Bears argue that rising costs and heavier R&D could cap earnings power, and the margin data gives them some support:
  • The move from a 23.9% to 16.4% margin lines up with the cautious view that higher spending and pricing pressure can squeeze profitability, even with neuroscience products contributing meaningfully to revenue.
  • At the same time, trailing basic EPS for the last 12 months sits at US$1.47, which is still firmly positive, so the bearish case hinges more on how long the margin compression persists rather than on any current loss making profile.

Skeptics are watching whether this margin reset is temporary or the new normal, and the detailed Bear and Bull write ups lay out both sides of that debate 🐻 Alkermes Bear Case.

Fast earnings forecasts versus slower revenue

• Analysts in the dataset expect earnings to grow about 55.2% per year while revenue is projected to grow around 9% per year, which is slower than the cited 11.2% growth rate for the broader US market.
• The bullish narrative leans heavily on this gap between earnings and revenue growth, and the trailing figures help frame how ambitious that is:
  • Over the past five years, earnings growth of roughly 49.9% per year is referenced in the data, which supports the idea that Alkermes has previously grown earnings faster than sales, but the latest 16.4% margin versus 23.9% a year earlier shows this has not been a straight line.
  • Consensus also assumes that current net income of about US$241.7 million on US$1.48b of trailing revenue can eventually scale further, so bulls are effectively betting that margins rebound closer to historical levels while revenue grows in line with or above the 9% forecast.

If you want to see how different investors connect these growth forecasts to specific products and pipeline milestones, the detailed Bull and Consensus narratives for Alkermes set out those scenarios side by side 🐂 Alkermes Bull Case.

Mixed valuation signals at US$36.25

• At a share price of US$36.25, Alkermes trades on a trailing P/E of 24.9x, above peer and biotech industry averages around 18x and 17.2x, while the dataset also cites a DCF fair value of US$103.44 and an analyst consensus price target of US$44.81.
• What stands out for both bulls and bears is how these numbers pull in different directions:
  • The higher P/E versus peers fits the cautious view that investors are already paying a premium for Alkermes, even though its trailing margin has slipped to 16.4%, which could limit how comfortable some investors feel about paying up today.
  • On the other hand, the gap between the current US$36.25 price, the US$44.81 consensus target and the US$103.44 DCF fair value is what supports the more optimistic camp, which points to strong forecast earnings growth of 55.2% per year as a reason the premium multiple might still be justified.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alkermes on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

The mix of optimism and concern in the data is clear, so do not wait around for a consensus to form. Put the numbers in context for your own portfolio, starting with the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Alkermes combines a compressed net profit margin of 16.4% with a relatively high 24.9x P/E, which can leave investors uneasy about paying a premium.

If you are concerned about paying up for earnings that currently come with thinner margins, it is worth urgently checking companies highlighted in the 51 high quality undervalued stocks that pair stronger value signals with more comfortable pricing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.